Aeglea BioTherapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Nov. 3, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that Aeglea's...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: ACC Source Type: news